X

Trial Profile

Phase II, Single-arm Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Olaparib (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms SUKSES-N2

Most Recent Events

16 Oct 2023 Results published in the Cancer.
08 Jun 2021 Results evaluating clinical efficacy of olaparib monotherapy or combination with ceralasertib presented at the 57th Annual Meeting of the American Society of Clinical Oncology
16 Feb 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com